Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Authors' conclusion
MACE risk was greater for participants with kidney impairment or damage than for those without. Semaglutide consistently reduced MACE risk across eGFR and UACR subgroups, indicating that semaglutide provides cardiovascular benefits in people with T2D and at high cardiovascular risk across a broad spectrum of kidney function and damage.
Study context
- Population
- People with T2D at high cardiovascular risk from SUSTAIN 6 and PIONEER 6, categorised by baseline eGFR (<45, ≥45-<60 vs ≥60 mL/min/1.73 m²) or UACR (≥30-≤300, >300 vs <30 mg/g)
- Comparison
- Semaglutide vs placebo across baseline eGFR and UACR subgroups
- Outcome
- First MACE
Methodological detailssubgroup analysis by baseline kidney parameters
- Subgroup analysis by baseline kidney parameters
Pooled result
As reported in the abstract
First MACE, semaglutide vs placebo by baseline eGFR and UACR subgroups
- Semaglutide consistently reduced major adverse cardiovascular events (MACE) risk vs placebo across all eGFR and UACR subgroups
- Semaglutide vs Placebo: interaction p value [pINT] > 0.05
Further pooled results
| Outcome | P value |
|---|---|
| HbA1cReduced regardless of baseline eGFR and UACR | pINT>0.05 |
MACE risk by baseline kidney parameters, independently of treatment (vs eGFR ≥60 or UACR <30 mg/g)
- eGFR ≥45-<60 mL/min/1.73 m², HR [95% CI]
- 1.36 [1.04;1.76]
- eGFR <45 mL/min/1.73 m², HR [95% CI]
- 1.52 [1.15;1.99]
- UACR ≥30-≤300 mg/g, HR [95% CI]
- 1.53 [1.14;2.04]
- UACR >300 mg/g, HR [95% CI]
- 2.52 [1.84;3.42]
Body weight
- Body weight (BW) reductions affected by baseline eGFR (pINT<0.001)
- BW reductions not affected by baseline UACR (pINT>0.05)
Safety
Serious adverse events
- More serious adverse events (SAEs) in lower eGFR or higher UACR subgroups vs reference subgroups
- Number of SAEs similar between semaglutide and placebo in each subgroup
Original publication
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Cardiovasc Diabetol. Published 24 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →